NASDAQ:ATOS Atossa Genetics (ATOS) Stock Price, News & Analysis $0.76 +0.00 (+0.33%) As of 11:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Atossa Genetics Stock (NASDAQ:ATOS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Atossa Genetics alerts:Sign Up Key Stats Today's Range$0.75▼$0.7750-Day Range$0.74▼$0.9452-Week Range$0.55▼$1.66Volume128,816 shsAverage Volume851,872 shsMarket Capitalization$98.69 millionP/E RatioN/ADividend YieldN/APrice Target$6.17Consensus RatingBuy Company Overview Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington. Read More Atossa Genetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreATOS MarketRank™: Atossa Genetics scored higher than 50% of companies evaluated by MarketBeat, and ranked 565th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingAtossa Genetics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAtossa Genetics has only been the subject of 2 research reports in the past 90 days.Read more about Atossa Genetics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Atossa Genetics are expected to decrease in the coming year, from ($0.22) to ($0.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atossa Genetics is -3.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atossa Genetics is -3.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtossa Genetics has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Atossa Genetics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.19% of the float of Atossa Genetics has been sold short.Short Interest Ratio / Days to CoverAtossa Genetics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Atossa Genetics has recently decreased by 6.85%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtossa Genetics does not currently pay a dividend.Dividend GrowthAtossa Genetics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.19% of the float of Atossa Genetics has been sold short.Short Interest Ratio / Days to CoverAtossa Genetics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Atossa Genetics has recently decreased by 6.85%, indicating that investor sentiment is improving significantly. News and Social Media2.2 / 5News Sentiment1.02 News SentimentAtossa Genetics has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Atossa Genetics this week, compared to 2 articles on an average week.Search InterestOnly 9 people have searched for ATOS on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows2 people have added Atossa Genetics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Atossa Genetics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.60% of the stock of Atossa Genetics is held by insiders.Percentage Held by InstitutionsOnly 12.74% of the stock of Atossa Genetics is held by institutions.Read more about Atossa Genetics' insider trading history. Receive ATOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atossa Genetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATOS Stock News HeadlinesAtossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference4 hours ago | prnewswire.comAtossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast CancerAugust 20, 2025 | prnewswire.comINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.August 28 at 2:00 AM | Traders Agency (Ad)Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate UpdateAugust 12, 2025 | prnewswire.comAtossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVAugust 1, 2025 | finance.yahoo.comAtossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast CancerJuly 29, 2025 | prnewswire.comCraig-Hallum Initiates Coverage of Atossa Therapeutics (ATOS) with Buy RecommendationJune 6, 2025 | msn.comAtossa Therapeutics to Present at the Jefferies Global Healthcare ConferenceJune 2, 2025 | prnewswire.comSee More Headlines ATOS Stock Analysis - Frequently Asked Questions How have ATOS shares performed this year? Atossa Genetics' stock was trading at $0.9441 at the beginning of the year. Since then, ATOS stock has decreased by 19.3% and is now trading at $0.7615. How were Atossa Genetics' earnings last quarter? Atossa Genetics Inc. (NASDAQ:ATOS) posted its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.01. When did Atossa Genetics' stock split? Shares of Atossa Genetics reverse split on the morning of Friday, April 20th 2018.The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 19th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. Who are Atossa Genetics' major shareholders? Atossa Genetics' top institutional investors include Ameriprise Financial Inc. (2.30%), Geode Capital Management LLC (1.01%), Jane Street Group LLC (0.36%) and Qube Research & Technologies Ltd (0.32%). Insiders that own company stock include Jonathan Finn, Steven C Quay and H Lawrence Remmel. View institutional ownership trends. How do I buy shares of Atossa Genetics? Shares of ATOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Atossa Genetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Atossa Genetics investors own include Zomedica (ZOM), AU Optronics (AUOTY), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), Waste Connections (WCN), American Water Works (AWK) and The RMR Group (RMR). Company Calendar Last Earnings8/12/2025Today8/28/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATOS CIK1488039 Webatossatherapeutics.com Phone(206) 588-0256Fax206-430-1288Employees8Year Founded2009Price Target and Rating Average Price Target for Atossa Genetics$6.17 High Price Target$7.50 Low Price Target$4.00 Potential Upside/Downside+709.8%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$25.50 million Net MarginsN/A Pretax MarginN/A Return on Equity-40.28% Return on Assets-37.10% Debt Debt-to-Equity RatioN/A Current Ratio9.17 Quick Ratio9.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.45 per share Price / Book1.69Miscellaneous Outstanding Shares129,170,000Free Float119,354,000Market Cap$98.36 million OptionableOptionable Beta0.92 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:ATOS) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Genetics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atossa Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.